The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...

Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and ...

The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group ...